Company History
Emtora Biosciences is a clinical stage life science company developing a novel formulation of rapamycin, eRapa™, for use in preventing the onset and recurrence of cancer. eRapa™ was originally developed for use in aging studies by Dr. Z. David Sharp and Dr. Randy Strong at the Barshop Institute for Longevity and Aging Studies at UT Health San Antonio in 2009. Their work uncovered numerous potential uses for eRapa™ in the fields of oncology, immunology, neurology, and trauma.
eRapa™ is the only pharmaceutical agent to demonstrate significantly increased health span and lifespan in rodent models, and Science, Nature, and Time magazines proclaimed the discovery of a special formulation of rapamycin to extend one’s life and health span among the most significant and exciting scientific breakthroughs of 2009.
eRapa™ was licensed for development to Emtora Biosciences (formerly Rapamycin Holdings, Inc.) in late 2012. Since that time, the company has launched eRapa-laced mouse chow products into the research market, completed second generation formulation development, completed numerous preclinical studies, obtained key patents, and completed a first-in-human Phase 1b clinical trial in low grade prostate cancer patients. Issued patents cover the novel formulation as a composition of matter, the manufacturing process for the formulation, and a variety of method of use patents covering our unique dosing and treatment regimens in multiple target disease indications.
Pipeline
The company completed a Phase 1 safety and dose escalation study in low grade prostate cancer patients in 2019. Phase 2 studies in Familial Adenomatous Polyposis (FAP) and non-muscle invasive bladder cancer (NMIBC) are underway.